Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera Maintenance in Hemodialysis Patients
NCT00661505Phase 3Completed
- Sponsor
- Roche
- Start
- May 2008
- Primary completion
- Jun 2010
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease (CKD-A), sponsored by Roche. Primary endpoint: Percentage of Participants Who Maintained Their Mean Hemoglobin Concentration Within +/- 1.0 Gram/Deciliter of Their Reference Hemoglobin Concentration and Between 10.0 and 12.0 Gram/Deciliter. Started May 2008; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00661505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661505.